News

The company reported a net loss of $6.65 million, or $0.21 per share, for the year ended December 31, 2008, compared to a net loss of $6.22 million,

Net loss for the year ended December 31, 2008 was $47 million, or $0.56 per diluted share, compared to a net loss of $99.3 million, or $1.39 per

Medline Industries, a privately held manufacturer and distributor of medical supplies, has signed a three-year agreement with Premier to provide advanced wound care products to the Catholic Healthcare

Astellas Pharma and XenoPort, a biopharmaceutical company, have reported preliminary top-line results from a Phase II clinical trial of ASP8825/XP13512 for the treatment of symptoms in moderate-to-severe primary

Vertex Pharmaceuticals, a biotechnology company, has announced that it will add two polymerase inhibitors to its hepatitis C virus drug development portfolio through a definitive agreement to acquire

A concurrent $6 million financing included Commonwealth Capital, Oxford Bioscience, Flagship Ventures, Life Sciences Partners, FLIR Systems, Healthcare Ventures, New Science Ventures and HLM Venture Partners. Jay Teich,

According to Trinity, TRI-stat is designed to measure HbA1c, also known as glycated hemoglobin, a measure of a patient’s average blood sugar control over the last two to

This represents the first time that the province of Quebec will standardize its entire system to one model of defibrillator, the company said. About 700 E Series defibrillators,

According to the company, The HairDX (RxR) genetic test for finasteride response will help doctors predetermine if patients will have a subtle, moderate, or great treatment response to